Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
None
Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease

agalsidase beta (FABRAZYME). In contrast, no randomized, controlled study of the efficacy of recombinant alpha-galactosidase A has been reported in heterozygotes for Fabry disease.

deficiency
renal function
fabrazyme
gla gene
agalsidase beta
  • 31 views
  • 07 Nov, 2020
  • 1 location
None
China Post-marketing Surveillance (PMS) Study of Fabrazyme®

This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with

replacement therapy
fabrazyme
cardiomyopathy
agalsidase beta
cornea verticillata
  • 0 views
  • 05 Nov, 2021
  • 1 location
None
China Post-marketing Surveillance (PMS) Study of Fabrazyme

This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese participants with

replacement therapy
fabrazyme
cardiomyopathy
agalsidase beta
cornea verticillata
  • 0 views
  • 09 Nov, 2021
  • 1 location
None
Study of the Effects of Fabrazyme Treatment on Lactation and Infants

The study will last for up to 2 years (24 months). Full participation for both mother and infant is 24 months, full participation of mother and development of infant is 24 months, while full participation of mother and no infant participation is 6 months

fabrazyme
agalsidase beta
  • 75 views
  • 24 Jan, 2021
  • 13 locations
None
Study of the Effects of Fabrazyme Treatment on Lactation and Infants

The study will last for up to 2 years (24 months). Full participation for both mother and infant is 24 months, full participation of mother and development of infant is 24 months, while full participation of mother and no infant participation is 6 months

fabrazyme
agalsidase beta
  • 0 views
  • 05 Nov, 2021
  • 2 locations
None
Fabry Disease Registry & Pregnancy Sub-registry

Fabry population as a whole; To evaluate the long-term safety and effectiveness of Fabrazyme Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international

deficiency
replacement therapy
fabrazyme
deficit
agalsidase beta
  • 456 views
  • 22 Oct, 2021
  • 563 locations
None
Fabry Disease Registry & Pregnancy Sub-registry

Fabry population as a whole; To evaluate the long-term safety and effectiveness of Fabrazyme® Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international

deficiency
replacement therapy
fabrazyme
deficit
agalsidase beta
  • 0 views
  • 05 Nov, 2021
  • 250 locations